Existing investor Gradient Ventures invested in a series B round that almost doubled the clinical research software provider's overall funding to $45m.
BenchSci, a Canada-based developer of drug-discovery analysis software, secured $22m on Tuesday in a series B round featuring Gradient Ventures, internet technology provider Google’s artificial intelligence fund.
The round was led by F-Prime Capital, a venture capital subsidiary of investment and financial services firm Fidelity, and included Northleaf Capital Partners, Inovia Capital, Golden Ventures and Real Ventures.
BenchSci’s software utilises artificial intelligence to locate inefficiencies in the drug development process and help researchers conduct more effective experiments.
F-Prime senior vice-president…
